- Home
- AMLX vs ARVN Comparison
AMLX vs ARVN Comparison
Compare AMLX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- ARVN
- Stock Information
- Founded
- AMLX 2014
- ARVN 2015
- Country
- AMLX United States
- ARVN United States
- Employees
- AMLX N/A
- ARVN N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- ARVN Health Care
- Exchange
- AMLX Nasdaq
- ARVN Nasdaq
- Market Cap
- AMLX 459.1M
- ARVN 456.2M
- IPO Year
- AMLX 2022
- ARVN 2018
- Fundamental
- Price
- AMLX $8.41
- ARVN $7.81
- Analyst Decision
- AMLX Strong Buy
- ARVN Buy
- Analyst Count
- AMLX 8
- ARVN 21
- Target Price
- AMLX $11.00
- ARVN $20.53
- AVG Volume (30 Days)
- AMLX 2.2M
- ARVN 1.8M
- Earning Date
- AMLX 08-07-2025
- ARVN 07-29-2025
- Dividend Yield
- AMLX N/A
- ARVN N/A
- EPS Growth
- AMLX N/A
- ARVN N/A
- EPS
- AMLX N/A
- ARVN N/A
- Revenue
- AMLX N/A
- ARVN $426,900,000.00
- Revenue This Year
- AMLX N/A
- ARVN $7.57
- Revenue Next Year
- AMLX N/A
- ARVN N/A
- P/E Ratio
- AMLX N/A
- ARVN N/A
- Revenue Growth
- AMLX N/A
- ARVN 498.74
- 52 Week Low
- AMLX $1.76
- ARVN $5.90
- 52 Week High
- AMLX $8.45
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- AMLX 80.57
- ARVN 54.65
- Support Level
- AMLX $5.97
- ARVN $7.58
- Resistance Level
- AMLX $6.86
- ARVN $8.31
- Average True Range (ATR)
- AMLX 0.57
- ARVN 0.39
- MACD
- AMLX 0.17
- ARVN 0.03
- Stochastic Oscillator
- AMLX 98.26
- ARVN 64.75
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.